Cleveland Clinic

Latest from Cleveland Clinic

Grading Valuable Aspects of Mesenchymal Cell Activity in Progressive MS: Jeffrey Cohen, MD

October 14, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic provided context on whether efficacy outcomes should be weighed more than mechanistic action when evaluating MSC-NTF cell therapies. [WATCH TIME: 3 minutes]